Key Highlights

  • Amneal Pharmaceuticals (NASDAQ:AMRX) shows USD 20.44, a decline of 4.97% against a 52-week high of USD 21.68, with a Market Capitalisation of USD 7.12 billion on the screen. All are unverified screener figures.
  • Third-quarter 2026 results on November 3, 2026 showed net Revenue of USD 863 million, up 10%, adjusted EBITDA of USD 207 million, up 30%, and adjusted diluted EPS of USD 0.26, up 53%.
  • On a GAAP basis Amneal lost USD 22 million, or USD 0.06 per share, against Net Income of USD 2 million a year earlier, citing non-recurring costs from the Kashiv Acquisition and a higher tax provision.
  • The company raised 2026 net revenue guidance to USD 3.15 billion to USD 3.25 billion and adjusted EPS to USD 1.04 to USD 1.08, but cut Operating Cash Flow guidance to USD 325 million to USD 375 million from USD 350 million to USD 400 million.

What the Report Showed

Amneal Pharmaceuticals (NASDAQ:AMRX) develops and sells generics, injectables, Biosimilars and specialty branded medicines. Affordable Medicines revenue rose 19% to USD 547 million on biosimilars, women's health patches and launches. Specialty revenue rose 20% to USD 150 million on CREXONT, BREKIYA and UNITHROID. AvKARE revenue fell 17% to USD 165 million, as expected, because of a non-recurring cardiovascular launch in the prior year. The company completed its Kashiv BioSciences acquisition around August 10, 2026. Published market data showed a 52-week range of USD 9.99 to USD 21.18 on October 26, 2026. The company also won FDA approval for its lanreotide injection around September 18, 2026 and launched it.

Why a Stock Can Touch a High and Then Fall

A 52-week high is the top of a one-year price range, and a stock that has run up sharply, here from USD 9.99 to above USD 21, can fall on good news if expectations were higher. Arithmetic on USD 20.44 and USD 9.99 shows the price about double the low. This research did not find a confirmed reason for the 4.97% drop. Features of the report a reader might weigh include the GAAP loss, a lower operating cash flow outlook, the AvKARE decline, and the rise in expected capital spending to about USD 150 million. These are possible readings and not confirmed causes. A strong run into Earnings means a lot of good news may already be in the price.

Risks and What to Watch

Adjusted EPS of USD 0.26 compares with USD 0.30 in the second quarter, which a reader may see as sequential softness. Consensus for the third quarter was not verified here. Analysts were positive before the report: JPMorgan raised its target to USD 24 from USD 22 and Oppenheimer began coverage at Outperform with a USD 27 target. Generic drug pricing, biosimilar competition and integration of Kashiv are the main risks, and a law firm announced an investigation on behalf of shareholders in July. The screen P/E of 42.65 is unverified. Watch cash flow conversion and the fourth-quarter outlook. Check the Cash Flow Statement in the full report.

Where Things Stand

Amneal fell 4.97% after touching a 52-week high for a reason that was not confirmed, and the report offers both sides: a 10% revenue rise, a 30% jump in adjusted EBITDA and higher revenue and EPS guidance, against a GAAP loss, weaker AvKARE sales and lower operating cash flow guidance. With the stock about double its 52-week low, expectations were high. The next dated catalyst is the fourth-quarter report, with no date confirmed. Any rebound would depend on cash flow conversion and biosimilar launches. A guidance raise on revenue and EPS is a positive, but cash flow conversion will decide how the market judges it.